Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. reported a net loss of $155.2 million for fiscal year 2025, driven by significant operating expenses of $209.6 million, primarily from research and development ($171.7 million) and general and administrative costs ($47.9 million). The company generated no revenue during the period. The net loss was partially offset by total other income of $54.3 million, including interest income...